

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Estepan Ian Michael</u> _____ (Last) (First) (Middle) <u>215 FIRST STREET</u> _____ (Street) <u>CAMBRIDGE MA</u> _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>12/14/2020</u>	3. Issuer Name and Ticker or Trading Symbol <u>Sarepta Therapeutics, Inc. [ SRPT ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ <u>Chief Financial Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	14,042	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	01/30/2016 <sup>(1)</sup>	01/30/2025	Common Stock	14,267	12	D	
Stock Option (right to buy)	01/30/2016 <sup>(1)</sup>	01/30/2025	Common Stock	1,533	12	D	
Stock Option (right to buy)	02/28/2017 <sup>(1)</sup>	02/28/2026	Common Stock	5,381	13.71	D	
Stock Option (right to buy)	02/28/2017 <sup>(1)</sup>	02/28/2026	Common Stock	2,069	13.71	D	
Stock Option (right to buy)	03/03/2018 <sup>(1)</sup>	03/03/2027	Common Stock	6,959	34.39	D	
Stock Option (right to buy)	03/03/2018 <sup>(1)</sup>	03/03/2027	Common Stock	5,541	34.39	D	
Stock Option (right to buy)	03/05/2019 <sup>(1)</sup>	03/05/2028	Common Stock	11,539	71.45	D	
Stock Option (right to buy)	03/05/2019 <sup>(1)</sup>	03/05/2028	Common Stock	1,861	71.45	D	
Stock Option (right to buy)	03/04/2020 <sup>(1)</sup>	03/04/2029	Common Stock	962	145.48	D	
Stock Option (right to buy)	03/04/2020 <sup>(1)</sup>	03/04/2029	Common Stock	39,038	145.48	D	
Stock Option (right to buy)	02/28/2021 <sup>(1)</sup>	02/28/2030	Common Stock	874	114.47	D	
Stock Option (right to buy)	02/28/2021 <sup>(1)</sup>	02/28/2030	Common Stock	31,626	114.47	D	

**Explanation of Responses:**

1. Represents the date upon which the first twenty-five percent of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter.

**Remarks:**

/s/ Ian Michael Estepan

12/14/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**